rAAV Gene Delivery for Propionic Acidemia Enzyme Deficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for propionic acidemia, such as dietary restrictions and antibiotics, do not address the underlying enzyme deficiency causing the disease, leading to poor long-term prognosis for patients.
Innovation Solution
Development of recombinant adeno-associated viral vectors (rAAV) that deliver functional PCCA or PCCB genes to patients with propionic acidemia, using AAV capsids and vector genomes containing specific sequences to correct the enzyme deficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dietary restriction and antibiotic therapy are used to manage propionic acidemia, then symptoms can be controlled temporarily, but the underlying enzyme deficiency remains unaddressed leading to poor long-term prognosis
Solution Approach 1:
The patent applies preliminary action by delivering functional PCCA or PCCB genes via rAAV vectors before the disease causes irreversible damage. The gene therapy is administered early to establish endogenous enzyme production, preventing the need for complex lifelong dietary and antibiotic regimens while addressing the root cause of the disease
2Reliability
If liver transplantation is performed to address enzyme deficiency, then PCC function can be restored, but the treatment is highly invasive with significant surgical risks and complications
Solution Approach 1:
The patent uses rAAV vectors as intermediaries to deliver functional genes directly to patient cells, bypassing the need for liver transplantation. The viral vectors serve as mediators that transfer genetic material in a non-invasive manner, restoring enzyme function without surgical intervention and avoiding associated risks such as rejection, infection, and surgical complications
3Ease of operation
If complex combinations of nutritional, cofactor, and antibiotic therapy are administered, then disease symptoms can be managed, but the treatment burden increases and long-term outcomes remain poor
Solution Approach 1:
The patent enables self-service by introducing functional genes that allow patient cells to produce the deficient PCC enzyme autonomously. Once the gene is delivered via rAAV, the patient's own cells continuously produce the necessary enzyme without requiring external administration of nutritional supplements, cofactors, or antibiotics, thereby simplifying the treatment regimen while improving long-term outcomes
Data Source
AI summary
This present disclosure provides adeno-associated viral vectors, recombinant adeno-associated virus (rAAV), and methods of their use in gene therapy for treating propionic acidemia (PA). Also provided are pharmaceutical compositions comprising a recombinant adeno-associated virus of the invention and a pharmaceutically acceptable carrier or excipient. These pharmaceutical compositions may be useful in gene therapy for the treatment of PA caused by mutations in propionyl-CoA carboxylase α-subunit (PCCA) or mutations in propionyl-CoA carboxylase β-subunit (PCCB).